查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1676930

联合脊髓灰质炎疫苗市场按疫苗类型、接种途径、技术、新兴市场发展阶段和最终用户划分 - 2025-2030 年全球预测

Combined Polio Vaccine Market by Vaccine Type, Route Of Administration, Technology, Development Stage, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计 2024 年脊髓灰质炎疫苗市场规模将达到 28.6 亿美元，2025 年将达到 29.7 亿美元，预计复合年增长率为 3.98%，到 2030 年将达到 36.2 亿美元。

主要市场统计数据
基准年 2024 年 28.6亿美元
预计 2025 年 29.7 亿美元
预测年份 2030 36.2亿美元
复合年增长率（%） 3.98％

随着全球卫生系统重新考虑其免疫策略，联合脊髓灰质炎疫苗市场正在转变。近年来，将多种疫苗製剂合併为单一剂量不仅为提高疫苗接种覆盖率而且简化公共卫生物流提供了绝佳机会。这项创新解决了对高效疫苗接种的迫切需求，特别是在医疗资源匮乏的地区。联合疫苗概念的演变植根于数十年的临床研究、科学合作和进步的公共卫生政策。随着对根除脊髓灰质炎的重新关注，政策制定者、研究人员和产业领导者一直在寻求疫苗接种方法的改进，以提供全面的保护，同时降低多次注射的成本和复杂性。

此外，对能够透过单一配方覆盖多种病原体的疫苗的需求不断增长，证实了相关人员已准备好接受创新的医疗保健解决方案。这种疫苗整合不仅满足了紧急的疫苗接种目标，也加强了预防性医疗基础设施的策略重要性。随着疾病模式的演变和新的健康风险的出现，联合疫苗的角色将变得更加重要。在这种动态环境中，市场正在进行密集的研究、快速的技术改进和监管支持，为疫苗接种和公共卫生结果的突破铺平了道路。

改变脊髓灰质炎联合疫苗市场

疫苗技术的最新进展和全球公共卫生重点的转变极大地改变了联合脊髓灰质炎疫苗的格局。创新研发已使疫苗将多种成分组合成更有效的製剂，大大减轻了医护人员面临的后勤负担。这一发展出现在人们对具有成本效益的疫苗接种计划的需求日益增长的背景下，这些计划需要更少的剂量并提供针对变异病毒的持久保护。

同时，数位健康和​​即时资料分析的新兴趋势正在为决策者提供可行的见解。这些技术将简化临床试验和监管审查，使联合疫苗能够更快进入市场。此外，公众意识的提高和政府主导的健康宣传活动正在增加疫苗接种，进一步推动市场发展势头。这种充满活力的环境的特征是生物技术公司、研究机构和政府机构之间的战略伙伴关係，协调应对现有和未来的健康挑战。

市场的发展将以对供应链中断和倾向于全面医疗保健解决方案的消费行为改变等挑战的灵活回应为标誌。由于传统的疫苗接种方法似乎越来越不足以应对现代健康危机，联合疫苗策略提供了一个有希望的替代方案。疫苗配方的不断改进和严格的上市后监测确保了公众对疫苗接种计划的坚定信心。摘要，这些变革性转变标誌着科学进步与实际健康解决方案融合的新时代的到来，有望显着改善全球公共卫生状况。

脊髓灰质炎联合疫苗市场的关键细分洞察

对联合脊髓灰质炎疫苗市场的详细研究揭示了清晰的细分见解，这对于了解其成长轨迹和策略方向至关重要。市场根据疫苗类型进行分析，包括二价、单价和三价疫苗等剂型。每种配方都有其自身的优势和挑战，需要采用独特的方法进行临床应用和法规遵循。

此外，给药途径在市场差异化中起着关键作用，从注射剂到口服剂型，针对不同的流行病学环境和患者群体进行最佳化。灭活脊髓灰质炎疫苗、减毒活病毒疫苗和次单位疫苗对安全性和免疫抗原性效率的贡献不同，可满足不同的公共卫生需求。

开发阶段的划分反映了疫苗研发过程的严谨与漫长。关键临床试验，包括 I 期、II 期、III 期甚至临床前研究，都表明人们正在做出巨大努力来确保每种组合疫苗的安全性和有效性。此外，包括诊所、社区健康中心、医院和公共卫生实验室在内的最终用户部门凸显了这些疫苗应用的医疗保健环境的广度。每个细分市场都带来了复杂性和机会，塑造了脊髓灰质炎结合疫苗的策略市场格局。

目录

第 1 章 简介

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 出生率上升和人口成长推动了全部区域对儿童疫苗的需求
      • 更重视预防保健和推广联合疫苗
      • 政府和非政府支持宣传活动促进疫苗接种和分发
    • 限制因素
      • 低温运输物流和运输的复杂性，以确保疫苗在分发过程中保持有效性
    • 机会
      • 增加对改善低温运输基础设施的投资，以实现最佳脊髓灰质炎疫苗联合效力
      • 正在进行的研究和开发旨在改善疫苗在不同气候条件下的储存和长期保存
    • 任务
      • 在全球多个市场获得核准面临重大监管障碍
  • 市场区隔分析
    • 疫苗类型：越来越需要一种针对两种脊髓灰质炎病毒株并平衡覆盖率和成本效益的二价疫苗
    • 发展阶段：
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6.脊髓灰质炎联合疫苗市场（依疫苗类型）

  • 二价疫苗
  • 单价疫苗
  • 三价疫苗

7.脊髓灰质炎联合疫苗市场（依接种途径划分）

  • 注射
  • 口服

8.脊髓灰质炎联合疫苗市场（依技术划分）

  • 灭活脊髓灰质炎病毒疫苗
  • 减毒活疫苗
  • 次单位疫苗

9.脊髓灰质炎联合疫苗市场（依开发阶段）

  • I期临床试验
  • II 期临床试验
  • III 期临床试验
  • 临床前试验

10.脊髓灰质炎联合疫苗市场（依最终用户划分）

  • 诊所
  • 社区健康中心
  • 医院
  • 公共卫生研究所

11. 美洲综合脊髓灰质炎市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

12. 亚太地区脊髓灰质炎联合疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

13. 欧洲、中东和非洲联合脊髓灰质炎疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十四章 竞争格局

  • 2024 年市场占有率分析
  • FPNV 定位矩阵，2024 年
  • 竞争情境分析
  • 战略分析与建议

公司列表

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bharat Immunologicals and Biologicals Corporation Limited
  • Biological E. Limited
  • BioNTech SE
  • CSL Limited
  • Daiichi Sankyo Company, Limited.
  • GlaxoSmithKline PLC
  • Haffkine Bio-Pharmaceutical Corporation Ltd
  • Incepta Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • Zydus Lifesciences Limited
Product Code: MRR-3E7318E8371A

The Combined Polio Vaccine Market was valued at USD 2.86 billion in 2024 and is projected to grow to USD 2.97 billion in 2025, with a CAGR of 3.98%, reaching USD 3.62 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 2.86 billion
Estimated Year [2025] USD 2.97 billion
Forecast Year [2030] USD 3.62 billion
CAGR (%) 3.98%

The combined polio vaccine market is transforming as global health systems recalibrate their immunization strategies. In recent years, the integration of multiple vaccine formulations into a single dose has presented a tremendous opportunity to not only enhance immunization coverage but also streamline public health logistics. This innovation addresses the critical need for efficient and effective immunization, particularly in regions where healthcare resources are stretched thin. The evolution of the combined vaccine concept is rooted in decades of clinical research, scientific collaboration, and progressive public health policies. With the renewed focus on eliminating polio, policymakers, researchers, and industry leaders have sought to refine vaccine delivery methods that offer comprehensive protection while cutting down on costs and complexities associated with administering multiple injections.

Furthermore, the rising demand for vaccines that can cover a spectrum of pathogens within a single formulation underscores the readiness of stakeholders to embrace innovative healthcare solutions. This consolidation of vaccines not only meets urgent immunization targets but also reinforces the strategic importance of preventive healthcare infrastructure. As disease patterns evolve and new health risks emerge, the role of combined vaccines becomes even more significant. In this dynamic environment, the market is witnessing a period of vigorous research, rapid technological enhancements, and regulatory support that together pave the way for groundbreaking advancements in vaccine delivery and public health outcomes.

Transformative Shifts in the Vaccine Landscape

Recent advancements in vaccine technology and a shift in global public health priorities have set the stage for transformative changes in the combined polio vaccine landscape. Innovative research has led to the development of vaccines that integrate multiple components into single, more potent formulations, drastically reducing the logistical burdens faced by healthcare providers. Such developments have been fueled by an increasing demand for cost-effective immunization programs that require fewer doses and offer extended protection against mutated strains.

At the same time, emerging trends in digital health and real-time data analytics are empowering decision-makers with actionable insights. These technologies streamline clinical trials and regulatory reviews, enabling faster market entry for combined vaccine formulations. Additionally, enhanced public awareness and government-led health campaigns have increased vaccine uptake, further accelerating market momentum. This dynamic environment is characterized by strategic partnerships between biotech companies, research institutions, and government bodies that work in harmony to address both existing and future health challenges.

Market evolution is marked by an agile response to challenges such as supply chain disruptions and shifts in consumer behavior that lean towards integrated healthcare solutions. As traditional vaccine delivery methods appear increasingly inadequate in addressing modern health crises, the combined vaccine strategy offers a promising alternative. The continual refinement of vaccine formulations coupled with robust post-market surveillance assures that public confidence in vaccination programs remains unwavering. In summary, these transformative shifts highlight a new era of convergence between scientific advancement and practical health solutions, promising significant improvements in public health globally.

Key Segmentation Insights in the Combined Polio Vaccine Market

A closer examination of the combined polio vaccine market reveals distinct segmentation insights that are critical to understanding its growth trajectory and strategic direction. The market is analyzed based on vaccine type, which encompasses formulations such as bivalent, monovalent, and trivalent vaccines. Each formulation presents unique benefits and challenges, necessitating tailored approaches for clinical application and regulatory compliance.

Additionally, the route of administration plays a crucial role in market differentiation, where solutions ranging from injectable administration to oral administration have been optimized to suit diverse epidemiological settings and patient demographics. The incorporation of advanced technologies is another key segment; inactivated poliovirus vaccines, live attenuated vaccines, and subunit vaccines each contribute differently to safety profiles and immunogenicity efficiencies, thus catering to varied public health requirements.

The segmentation based on development stage further reflects the rigorous and often lengthy process involved in vaccine research and development. Critical clinical trials, including phase I, phase II, phase III, and even pre-clinical research, indicate the robust efforts being invested in ensuring that each combined vaccine is both safe and effective. Moreover, the end user segment, which includes clinics, community health centers, hospitals, and public health laboratories, underscores the broad spectrum of healthcare settings where these vaccines are being implemented. Each of these segments contributes a layer of complexity and opportunity that collectively shapes the strategic market narrative for combined polio vaccinations.

Based on Vaccine Type, market is studied across Bivalent Vaccine, Monovalent Vaccine, and Trivalent Vaccine.

Based on Route Of Administration, market is studied across Injectable Administration and Oral Administration.

Based on Technology, market is studied across Inactivated Poliovirus Vaccines, Live Attenuated Vaccines, and Subunit Vaccines.

Based on Development Stage, market is studied across Phase I Clinical Trials, Phase II Clinical Trials, Phase III Clinical Trials, and Pre-Clinical Trials.

Based on End User, market is studied across Clinics, Community Health Centers, Hospitals, and Public Health Laboratories.

Key Regional Insights Across Major Global Markets

Exploring regional dynamics reveals distinctive characteristics in the adoption and application of combined polio vaccines. In the Americas, mature healthcare frameworks and proactive immunization policies have facilitated seamless integration of innovative vaccine solutions into public health programs. Meanwhile, the Europe, Middle East & Africa region presents a varied landscape where robust regulatory environments and varying levels of healthcare infrastructure coexist, driving a need for adaptable vaccine strategies that cater to both high-income and emerging markets.

In the Asia-Pacific region, rapid industrial growth, increasing population densities, and rising health awareness contribute to a dynamic market environment. Here, the demand for efficacious and economically viable immunization solutions is particularly pronounced as nations strive to meet ambitious vaccination targets while managing resource limitations. Collectively, these regional insights reflect not only the diverse market challenges but also the vast opportunities for strategic investment and public-private collaboration in the ongoing battle to eradicate polio.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Company Insights Shaping the Vaccination Landscape

An in-depth evaluation of industry players reveals that a diverse range of companies is actively shaping the combined polio vaccine market. Renowned pharmaceutical entities such as Astellas Pharma Inc. and AstraZeneca PLC are making significant strides by investing heavily in research and technology innovations. Companies like Bharat Immunologicals and Biologicals Corporation Limited and Biological E. Limited have carved out vital roles by catering to emerging economies and developing customized vaccine solutions for diverse demographic needs.

Other major industry participants, including BioNTech SE, CSL Limited, and Daiichi Sankyo Company, Limited, play important roles in advancing the scientific underpinnings of vaccine development through robust clinical trials and strategic partnerships. GlaxoSmithKline PLC and Haffkine Bio-Pharmaceutical Corporation Ltd contribute their global expertise in vaccine safety and distribution, which is crucial in maintaining public trust during the immunization process. Further, entities such as Incepta Pharmaceuticals Ltd., Merck & Co., Inc., and Mitsubishi Tanabe Pharma Corporation have demonstrated a commitment to innovation that transcends geographical boundaries, ensuring that the latest technologies reach those in need.

In addition, Panacea Biotec Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, and Zydus Lifesciences Limited represent a robust cross-section of the market. Their collective efforts are cementing the foundation for widespread vaccine acceptance and implementation, ultimately contributing to enhanced global immunization outcomes. Together, these companies not only drive market competition but also foster a spirit of innovation that is essential for sustaining long-term health improvements.

The report delves into recent significant developments in the Combined Polio Vaccine Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., AstraZeneca PLC, Bharat Immunologicals and Biologicals Corporation Limited, Biological E. Limited, BioNTech SE, CSL Limited, Daiichi Sankyo Company, Limited., GlaxoSmithKline PLC, Haffkine Bio-Pharmaceutical Corporation Ltd, Incepta Pharmaceuticals Ltd., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Panacea Biotec Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, and Zydus Lifesciences Limited. Actionable Recommendations for Industry Leaders

Industry leaders are encouraged to consider a multifaceted strategy to fully capitalize on the dynamic potential within the combined polio vaccine market. To begin with, a continuous investment in research and development activities is crucial in meeting both current and emerging health challenges. Embracing cutting-edge biotechnology and digital health solutions allows companies to achieve faster clinical trial results and enhance vaccine performance. By intensifying efforts in safety protocols and efficacy studies, leaders can build greater public confidence and streamline complex regulatory pathways.

Furthermore, fostering strategic alliances with local healthcare providers and global research institutions will be instrumental in adapting to diverse market needs. This includes developing region-specific product variants and leveraging localized data to tailor marketing strategies effectively. Taking a proactive approach in identifying and mitigating potential supply chain risks, especially in regions prone to logistical challenges, will ensure consistent vaccine availability and robust distribution networks.

In addition, there should be a concerted focus on workforce training and capacity building. Ensuring that healthcare professionals are well-versed in the latest technologies and vaccination methodologies is key to optimizing immunization results. Finally, a customer-centric strategy that emphasizes clear communication and transparency can facilitate trust among end users, be they clinics, community health centers, or major hospitals. The synthesis of these strategies offers a pathway for industry leaders to not only secure a competitive edge but also contribute meaningfully to global health initiatives.

Conclusion: A Forward-Thinking Perspective for Global Immunization

In conclusion, the combined polio vaccine market is at a strategic crossroads where innovation meets urgent global health needs. The interplay of technological advancements, targeted segmentation, and regional dynamics heralds a promising future for enhanced immunization strategies. With key industry players steering the market through innovation and comprehensive research, the path forward is defined by proactive collaboration and adaptive strategies. This dynamic environment calls for industry leaders to remain vigilant, agile, and committed to continuous improvement as they contribute to the broader mission of disease eradication.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising birth rates and population growth bolster demand for pediatric vaccines across regions
      • 5.1.1.2. Growing emphasis on preventive health care encourages uptake of combination vaccines
      • 5.1.1.3. Government and non-governmental support campaigns enhance vaccine uptake and distribution
    • 5.1.2. Restraints
      • 5.1.2.1. Complexities in cold chain logistics and transportation for maintaining vaccine efficacy during distribution
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising investment in cold chain infrastructure improvements for optimal combined polio vaccine efficacy
      • 5.1.3.2. Ongoing research and development for improved vaccine storage and longevity in various climates
    • 5.1.4. Challenges
      • 5.1.4.1. Significant regulatory hurdles for obtaining approval across multiple global markets
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Vaccine Type: Increasing need for a bivalent vaccine targeting two poliovirus strains delivering a balance between coverage and cost-effectiveness
    • 5.2.2. Development Stage:
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Combined Polio Vaccine Market, by Vaccine Type

  • 6.1. Introduction
  • 6.2. Bivalent Vaccine
  • 6.3. Monovalent Vaccine
  • 6.4. Trivalent Vaccine

7. Combined Polio Vaccine Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Injectable Administration
  • 7.3. Oral Administration

8. Combined Polio Vaccine Market, by Technology

  • 8.1. Introduction
  • 8.2. Inactivated Poliovirus Vaccines
  • 8.3. Live Attenuated Vaccines
  • 8.4. Subunit Vaccines

9. Combined Polio Vaccine Market, by Development Stage

  • 9.1. Introduction
  • 9.2. Phase I Clinical Trials
  • 9.3. Phase II Clinical Trials
  • 9.4. Phase III Clinical Trials
  • 9.5. Pre-Clinical Trials

10. Combined Polio Vaccine Market, by End User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Community Health Centers
  • 10.4. Hospitals
  • 10.5. Public Health Laboratories

11. Americas Combined Polio Vaccine Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Combined Polio Vaccine Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Combined Polio Vaccine Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. VitriVax secures USD 3.6M grant from Gates Foundation to innovate next-gen polio vaccine formulations
    • 14.3.2. Rice Bioengineers receive USD 3.4m grant to innovate polio vaccine integration
    • 14.3.3. Sanofi secures approval for IMOVAX-polio vaccine in India
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Astellas Pharma Inc.
  • 2. AstraZeneca PLC
  • 3. Bharat Immunologicals and Biologicals Corporation Limited
  • 4. Biological E. Limited
  • 5. BioNTech SE
  • 6. CSL Limited
  • 7. Daiichi Sankyo Company, Limited.
  • 8. GlaxoSmithKline PLC
  • 9. Haffkine Bio-Pharmaceutical Corporation Ltd
  • 10. Incepta Pharmaceuticals Ltd.
  • 11. Merck & Co., Inc.
  • 12. Mitsubishi Tanabe Pharma Corporation
  • 13. Panacea Biotec Ltd.
  • 14. Pfizer Inc.
  • 15. Sanofi S.A.
  • 16. Serum Institute of India Pvt. Ltd.
  • 17. Sinovac Biotech Ltd.
  • 18. Takeda Pharmaceutical Company Limited
  • 19. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. COMBINED POLIO VACCINE MARKET MULTI-CURRENCY
  • FIGURE 2. COMBINED POLIO VACCINE MARKET MULTI-LANGUAGE
  • FIGURE 3. COMBINED POLIO VACCINE MARKET RESEARCH PROCESS
  • FIGURE 4. COMBINED POLIO VACCINE MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. COMBINED POLIO VACCINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. COMBINED POLIO VACCINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. COMBINED POLIO VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. COMBINED POLIO VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY BIVALENT VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY MONOVALENT VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY TRIVALENT VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY INJECTABLE ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY INACTIVATED POLIOVIRUS VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PHASE I CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PHASE II CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PRE-CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 237. COMBINED POLIO VACCINE MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 238. COMBINED POLIO VACCINE MARKET, FPNV POSITIONING MATRIX, 2024